A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 22 Jul 2021 Planned End Date changed from 31 May 2021 to 31 May 2022.
- 22 Jul 2021 Planned primary completion date changed from 31 May 2021 to 31 May 2022.